Interview with CEO Anders Rylander
Company presentation May 2020
Capital Market Day 11th of May 2020
Nordnet Nordic Invest, Capital Markets Seminar, 6 mars 2020
Aktiedagen Lund 28 januari
Panelsamtal: Framtidens behandling av cancer på Aktiedagen 28 januari i Lund
Pareto Securities life science analytiker går igenom Biovica
Audiocast, December 6, 2019. Q2 Interim Report
Audiocast, September 19, 2019. Update on clinical development progress
Pareto Securities’ 10th Annual Health Care Conference in Stockholm 5th September 2019
Interview with Anders Rylander, CEO
Management presentation directed issue April 2019
Web-cast telephone conference, at 09:00 am CET, March 21.
The live webcast and a recorded on-demand version including the presentation material will be accessible at:
Börsveckans Småbolagsdag 19 februari 2019 – intervju
Börsveckans Småbolagsdag 19 februari 2019 – presentation
RedEye LifeScience Dag den 21 november 2018
Biovica’s vision – ‘best-possible-treatment’ from day one
We envisage a future where every patient receives the best possible therapy from the very first day of treatment. Where medical decisions are tailored to individual needs rather than practices that work for some but not for others. Our assays will help clinicians predict and monitor response to treatment with unrivalled speed and precision. We will make ‘best-possible-treatment’ a reality.
Biovica’s mission – more informed treatment decisions
Biovica improves the way cancer is treated today regarding patient survival and quality-of-life as well as the costs borne by society. By implementing Biovica’s biomarker assays into current treatment paradigms, clinicians can make more informed decisions about medical treatment and follow-up and thereby deliver the right treatment to the right patient at the right time.